九源基因(02566)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02566 九源基因

交易中 05-22 15:37:58

6.420

-0.160

-2.43%

最高6.470	最低6.200	成交量4.82万
今开6.280	昨收6.580	日振幅4.10%
总市值15.54亿	流通市值15.54亿	总股本2.42亿
成交额30.10万	换手率0.02%	流通股本2.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02566","market":"HK","secType":"STK","nameCN":"九源基因","latestPrice":6.42,"timestamp":1779433917937,"preClose":6.58,"halted":0,"volume":48200,"delay":0,"changeRate":-0.024316109422492422,"floatShares":242000000,"shares":242000000,"eps":0.6501951009943503,"marketStatus":"交易中","change":-0.16,"latestTime":"05-22 15:37:58","open":6.28,"high":6.47,"low":6.2,"amount":301048,"amplitude":0.041033,"askPrice":6.42,"askSize":4400,"bidPrice":6.35,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":0.6501951009943503,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779437400000},"marketStatusCode":2,"adr":0,"listingDate":1732723200000,"exchange":"SEHK","adjPreClose":6.58,"dividendRate":0.009934,"openAndCloseTimeList":[[1779413400000,1779422400000],[1779426000000,1779436800000]],"volumeRatio":1.513566,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02566","defaultTab":"news","newsList":[{"id":"1121924486","title":"九源基因完成136,302,015股内资及外资股转换H股，已发行股本大幅变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1121924486","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121924486?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:11","pubTimestamp":1778760664,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年5月14日发布翌日披露报表，宣布将105,302,015股内资股与31,000,000股非上市外资股转换为合计136,302,015股H股，并于2026年5月15日起在香港联合交易所有限公司上市交易。该新增H股数量占本次变动前已发行股份总数的约56.44%。本次转换完成后，公司的H股由原有105,214,385股增至241,516,400股，另持有库藏股3,882,400股，变动后公司已发行股本共计245,398,800股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"九源基因完成136,302,015股内资及外资股转换H股，已发行股本大幅变动","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635271497","title":"九源基因(02566)：完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2635271497","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635271497?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:44","pubTimestamp":1778759066,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，1.36亿股未上市股份转换为H股已于2026年5月14日完成，而有关经转换H股将于2026年5月15日上午9时正开始于联交所上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634829282","title":"九源基因(02566)更名为“杭州九源基因生物医药股份有限公司”","url":"https://stock-news.laohu8.com/highlight/detail?id=2634829282","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634829282?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:19","pubTimestamp":1778505581,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 发布公告，公司已于2025年4月17日取得香港公司注册处处长签发的注册非香港公司变更名称注册证明书，确认根据公司条例第16部在香港注册的公司英文名称已由“Hangzhou Jiuyuan Gene Engineering Co., Ltd.”更改为“Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.”，而中文名称已由“杭州九源基因工程股份有限公司”更改为“杭州九源基因生物医药股份有限公司”。更改公司名称后，公司的股份代号、中文股票简称及英文股票简称保持不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","XBI","BK4588","02566","BK4581","161726","399441","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633845393","title":"九源基因(02566)：联交所就实施H股全流通授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2633845393","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633845393?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:32","pubTimestamp":1778239936,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，公司已向联交所上市委员会申请批准公司根据转换公司12名参与股东持有的1.36亿股非上市股份转换的1.36亿股H股上市及买卖。公司欣然宣布，联交所已于2026年5月8日授出上市批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178315599","title":"九源基因4月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178315599","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178315599?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:12","pubTimestamp":1778058772,"startTime":"0","endTime":"0","summary":"2026年5月6日，杭州九源基因生物医药股份有限公司披露截至2026年4月30日的证券变动月报表。报告期内，公司注册股本为人民币2.45亿元，无新增发行、回购或注销股份，整体股本结构保持稳定。截至4月底，公司普通股共分为三类：H股、内资股与非上市外资股。上述数据与上月持平，未发生任何变动。公司确认已达到香港联交所相关公众持股量要求。本次公告由联席公司秘书黄秀签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633890770","title":"九源基因(02566)：公众持股量约为22.22% 将尽最大努力于第二季度内恢复公众持股量","url":"https://stock-news.laohu8.com/highlight/detail?id=2633890770","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633890770?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:34","pubTimestamp":1778056443,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，于本公告日期，本公司的公众持股量约为22.22%，该比例仍低于上市规则第19A.28B条所规定的最低规定百分比。本公司正根据该等公告先前所披露的预期时间表实施公众持股量恢复计划(即H股全流通)，并将尽最大努力于2026年第二季度内恢复其公众持股量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185513701","title":"九源基因Jy54注射液获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1185513701","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185513701?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:21","pubTimestamp":1777375270,"startTime":"0","endTime":"0","summary":"杭州九源基因工程股份有限公司宣布，其研发的Jy54注射液已正式获得中国国家药品监督管理局的临床试验默示许可。该生物制品即将开展针对特定适应症的临床研究，标志着公司创新药研发管线取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151450629","title":"九源基因Jy54注射液获国家药监局批准在中国开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1151450629","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151450629?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:20","pubTimestamp":1777371634,"startTime":"0","endTime":"0","summary":"杭州九源基因工程股份有限公司宣布，其研发的Jy54注射液已正式获得中国国家药品监督管理局（NMPA）的临床试验批准。该批准标志着Jy54注射液可在国内进入临床研究阶段，为公司创新药管线的发展注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630870132","title":"国产司美格鲁肽“首证”缓发？多家申报企业称专利悬崖过后还有数据保护期","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870132","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630870132?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:05","pubTimestamp":1777107938,"startTime":"0","endTime":"0","summary":"司美格鲁肽保护期的延长或将导致国产司美的“内卷”进一步加剧。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260425/20260425170827_99857.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260425/20260425170827_99857.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","NVOH","BK0028","IE00BZ1G4Q59.USD","02566","BK0239","BK0187","01513","LU1093756325.SGD","BK4532","LLY","BK4588","IE00BKVL7J92.USD","000513","NVO","BK4599","BK0188","LU1093756168.USD","NVOX","BK4007","BK4585","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1191577457","title":"九源基因授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1191577457","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191577457?lang=zh_cn&edition=full","pubTime":"2026-04-24 19:47","pubTimestamp":1777031227,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司最新公告显示，公司已在股东周年大会上通过特别决议，授予董事会最高可回购不超过公司已发行H股总数10%的授权。基准日期参照2025年12月31日的已发行H股总量约1.05亿股，此次购回授权对应上限约为1052万股。董事会声明，此举符合公司及全体股东的最佳利益。公告还显示，九源基因拟于2026年6月15日召开股东周年大会，相关决议将于会议结束后最终实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九源基因授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186101704","title":"九源基因将于2026年07月30日派发末期股息每股0.06元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186101704","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186101704?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:35","pubTimestamp":1776951356,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司宣布最新股息分派方案。根据公告，该公司已于2026年4月23日发布更新公告，内容显示将派发截至2025年12月31日止年度的末期股息。股东批准日期为2026年6月15日，除净日为2026年6月17日，最后过户登记日为2026年6月18日16:30，股权登记日为2026年6月24日，正式派息日为2026年7月30日。公告披露，末期股息为每10股0.57元人民币，折合每股约0.06元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九源基因将于2026年07月30日派发末期股息每股0.06元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629374338","title":"九源基因(02566)将于7月30日派发末期股息每10股0.57元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629374338","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629374338?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:33","pubTimestamp":1776951218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，该公司将于2026年7月30日派发末期股息每10股0.57元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","VIG","BK4588","02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181912885","title":"九源基因3月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1181912885","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181912885?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:36","pubTimestamp":1775640987,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年4月8日发布月报文件，披露2026年3月31日止当月股份变动情况。根据公告，报告期内公司股本结构保持稳定，未发生新增发行、购回、注销或库藏股变动。公告显示，九源基因的H股已符合适用的公众持股量要求。九源基因表示将继续遵守香港联交所《上市规则》及相关法律法规的要求，确保股本信息的透明披露与合规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125376683","title":"九源基因月度更新：公眾持股量22.22%，H股全流通完成後料升至約31.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125376683","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125376683?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:17","pubTimestamp":1775639820,"startTime":"0","endTime":"0","summary":"九源基因4月8日发布月度公告称，截至公告日，公司公眾持股量约为22.22%，仍低于香港上市规则第19A.28B条所规定的最低百分比。待相关H股在联交所主板上市后，且假设核心关联人士持股保持不变，公眾持股量预计将提升至约31.13%，届时将符合最低要求。九源基因提醒股东及潜在投资者在买卖股份时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624504952","title":"九源基因(02566)已就H股全流通事项向中国证监会完成备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2624504952","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624504952?lang=zh_cn&edition=full","pubTime":"2026-04-02 21:16","pubTimestamp":1775135770,"startTime":"0","endTime":"0","summary":"九源基因(02566)公布，于2026年4月2日，中国证监会向该公司发出备案通知书，内容有关H股全流通。根据备案通知书，公司已就H股全流通事项(内容有关12名公司股东所持的136,302,015股未上市股份转换为H股)向中国证监会完成备案。倘自备案通知书日期起计12个月内未完成股份转换，且公司仍有意进行该转换，则公司应当向中国证监会更新备案材料。公司将向联交所申请批准该等H股于联交所主板上市及买卖。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_46.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_46.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623288733","title":"九源基因(02566)建议委任黄文礼为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2623288733","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623288733?lang=zh_cn&edition=full","pubTime":"2026-03-31 01:24","pubTimestamp":1774891494,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，董事会建议委任黄文礼博士为独立非执行董事，建议委任独立非执行董事将自股东于股东周年大会上批准之日起生效至第一届董事会任期届满为止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623344650","title":"九源基因(02566)发布年度业绩 股东应占利润1.38亿元 拟派发末期股息每10股0.57元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623344650","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623344650?lang=zh_cn&edition=full","pubTime":"2026-03-30 23:19","pubTimestamp":1774883972,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 发布截至2025年12月31日止年度业绩，该集团取得收入13.06亿元公司;公司拥有人应占年内利润1.38亿元，较去年同期基本持平;每股基本盈利0.56元。拟每10股派发现金股息0.57元(含税)。公告称，报告期内，公司积极完成新品上市与推广工作，取得显著成效，已在20个省市获得市场准入。全年共实现销售收入人民币180万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","VIG","BK4588","02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162269070","title":"九源基因将于2026年7月30日派发末期股息每股0.057元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162269070","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162269070?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:16","pubTimestamp":1774880197,"startTime":"0","endTime":"0","summary":"九源基因\\n\\n根据公司公告，董事会已宣布截至2025年12月31日止年度的末期股息为每10股0.57元人民币，相当于每股0.057元人民币。上述股息须待计划于2026年6月15日召开的股东大会批准后，方可派发。\\n\\n根据公告，除净日定于2026年6月17日，持股登记的最后时间为2026年6月18日16时30分。公司将于2026年6月22日至6月24日暂停办理股份过户登记，并于2026年6月24日确定股东名单。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125248160","title":"九源基因（02566）公布1月股份变动月报，合计回购约77.44万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1125248160","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125248160?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:21","pubTimestamp":1773829312,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年3月18日披露2026年1月股份变动月报表，报告期为2026年1月。截至本月末，公司注册股本人民币245,398,800元，其中包括三类股份：H股、内资股及非上市外资股。H股方面，月初已发行流通股份数量为109,096,785股，当月合计回购774,400股，并将其持作库存股份，导致H股流通股份减少至108,322,385股，库存股份则增至774,400股。内资股和非上市外资股数量分别维持在105,302,015股及31,000,000股，报告期内无变动。截至1月末，公司股本总数保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620430440","title":"九源基因(02566)：JY47注射液新药临床试验申请获国家药监局临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2620430440","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620430440?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:21","pubTimestamp":1773739274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，集团自主开发的JY47注射液新药临床试验(IND)申请已获中国国家药品监督管理局临床试验默示许可，适应症为代谢功能障碍相关脂肪性肝炎(MASH)伴肝纤维化。该产品为集团研发的一款靶向SIRPα的单抗注射液。SIRPα是典型的抑制性受体，可与配体CD47以高亲和力结合。研究表明CD47-SIRPα信号通路在代谢性疾病相关的免疫调控中具有重要作用，SIRP拮抗剂可通过调节免疫细胞功能、改善组织微环境及代谢稳态，从而对代谢疾病进展产生积极影响。在MASH的体外类器官模型和体内疾病模型中，显示出良好的治疗潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.china-gene.com","stockEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.0573},{"period":"3month","weight":-0.284},{"period":"6month","weight":-0.0823},{"period":"1year","weight":0.0504},{"period":"ytd","weight":-0.1296}],"compareEarnings":[{"period":"1week","weight":-0.038},{"period":"1month","weight":-0.0416},{"period":"3month","weight":-0.0389},{"period":"6month","weight":0.0066},{"period":"1year","weight":0.0654},{"period":"ytd","weight":-0.0095}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州九源基因生物医药股份有限公司（原名：杭州九源基因工程股份有限公司）是一家主要从事研发、生产及商业化生物药品和医疗器械的中国公司。该公司专注于骨科、代谢疾病、肿瘤及血液治疗领域。该公司的骨科产品包括骨优导骨修复材料。该公司的肿瘤产品包括吉利芬、吉巨芬、吉欧停、吉芙惟、吉坦苏。该公司的血液产品包括吉派林、亿喏佳。该公司的产品主要用于治疗糖尿病、多发性骨髓瘤、血小板减少症、中性粒细胞减少症等疾病。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"九源基因","nameEN":"JIUYUAN GENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九源基因(02566)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九源基因(02566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九源基因,02566,九源基因股票,九源基因股票老虎,九源基因股票老虎国际,九源基因行情,九源基因股票行情,九源基因股价,九源基因股市,九源基因股票价格,九源基因股票交易,九源基因股票购买,九源基因股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九源基因(02566)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九源基因(02566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}